Price
Financials
Consolidated, Rs crore| Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35.24 | 32.29 | 37.20 | 43.87 | 44.58 | 46.50 | 44.70 | 37.26 | 44.42 | 56.87 |
| Expenses | 30.40 | 28.34 | 29.96 | 36.93 | 38.21 | 39.96 | 37.78 | 30.51 | 38.50 | 48.56 |
| Operating Profit | 4.84 | 3.95 | 7.24 | 6.94 | 6.37 | 6.54 | 6.92 | 6.75 | 5.92 | 8.31 |
| OPM % | 13.73% | 12.23% | 19.46% | 15.82% | 14.29% | 14.06% | 15.48% | 18.12% | 13.33% | 14.61% |
| Other Income | 0.15 | 0.11 | 0.33 | 0.19 | 1.09 | 0.32 | 0.22 | 0.30 | 0.22 | 0.42 |
| Interest | 0.81 | 0.99 | 1.07 | 1.31 | 1.41 | 1.44 | 1.36 | 1.75 | 2.08 | 1.71 |
| Depreciation | 0.88 | 0.88 | 0.84 | 0.86 | 1.36 | 0.93 | 0.94 | 1.02 | 1.39 | 1.47 |
| Profit before tax | 3.30 | 2.19 | 5.66 | 4.96 | 4.69 | 4.49 | 4.84 | 4.28 | 2.67 | 5.55 |
| Tax % | 25.76% | 29.68% | 25.27% | 30.24% | 23.24% | 29.62% | 26.24% | 25.70% | 29.21% | 28.65% |
| Net Profit | 2.44 | 1.54 | 4.23 | 3.47 | 3.60 | 3.16 | 3.58 | 3.17 | 1.88 | 3.96 |
| EPS in Rs | 1.26 | 0.80 | 1.78 | 1.51 | 1.73 | 1.52 | 1.61 | 1.24 | 0.82 | 1.89 |
| Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|
| Sales | 122 | 156 | 173 | 183 |
| Expenses | 104 | 130 | 147 | 155 |
| Operating Profit | 18 | 25 | 26 | 28 |
| OPM % | 15% | 16% | 15% | 15% |
| Other Income | 0 | 2 | 1 | 1 |
| Interest | 3 | 5 | 7 | 7 |
| Depreciation | 3 | 4 | 4 | 5 |
| Profit before tax | 12 | 19 | 16 | 17 |
| Tax % | 26% | 27% | 27% | |
| Net Profit | 9 | 14 | 12 | 13 |
| EPS in Rs | 4.66 | 6.26 | 5.24 | 5.56 |
| Dividend Payout % | 0% | 74% | 95% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | % | 6% | ||
| Compounded Profit Growth | % | % | % | -15% | ||
| Stock Price CAGR | % | % | 18% | 116% | ||
| Return on Equity | % | % | 12% | 10% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 18 | 18 | 19 |
| Reserves | 61 | 72 | 85 |
| Borrowings | 35 | 60 | 74 |
| Other Liabilities | 22 | 40 | 34 |
| Total Liabilities | 135 | 190 | 213 |
| Fixed Assets | 24 | 52 | 55 |
| CWIP | 2 | 3 | 3 |
| Investments | 2 | 3 | 5 |
| Other Assets | 108 | 131 | 150 |
| Total Assets | 135 | 190 | 213 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Cash from Operating Activity | 1 | 19 | 19 |
| Cash from Investing Activity | -3 | -45 | -20 |
| Cash from Financing Activity | 0 | 27 | 1 |
| Net Cash Flow | -1 | 1 | 0 |
| Free Cash Flow | 1 | 19 | 19 |
| CFO/OP | 26% | 97% | 93% |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 124 | 136 | 142 |
| Inventory Days | 172 | 176 | 181 |
| Days Payable | 90 | 76 | 73 |
| Cash Conversion Cycle | 205 | 236 | 251 |
| Working Capital Days | 148 | 100 | 93 |
| ROCE % | 17% | 13% |
| Dec 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 73.67% | 68.11% | 68.11% | 68.11% |
| FIIs | 0.71% | 1.21% | 1.02% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.00% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.60% | 1.59% | 1.59% |
| Public | 25.62% | 25.12% | 25.32% | 26.33% | 26.33% | 26.33% | 26.33% | 30.28% | 30.30% | 30.30% |
| No. of Shareholders | 925 | 1,043 | 1,213 | 1,586 | 1,695 | 1,519 | 1,489 | 1,564 | 1,499 | 1,554 |
Fundamentals
Market Cap₹ 419 Cr.
Current Price₹ 217
Stock P/E39.0
Book Value₹ 53.9
ROCE12.9 %
ROE10.4 %
Dividend Yield0.23 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)6%
Compounded Profit Growth (TTM)-15%
Consolidated figures.
Ownership
Promoter holding68.11% (-5.56 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | QMSMEDI | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +1.6% | -2.8% | +4.4 pts |
| 1 month | +21.3% | -6.8% | +28.1 pts |
| 3 months | +87.4% | -7.6% | +95.0 pts |
| 6 months | +167.7% | +0.4% | +167.3 pts |
| 1 year | +134.6% | -9.9% | +144.5 pts |
| 2 years | +75.8% | -13.6% | +89.4 pts |
| 3 years | +46.5% | +14.2% | +32.3 pts |
Red flags
| look | On NSE surveillance On NSE surveillance: ESM |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹57 Cr +22.3% vs Jun 2025.
Net profit ₹4 Cr +25.3%.
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Poly Medicure Ltd | 16,671 | 52.1 | 12.5 % |
| Molbio Diagnostics Ltd | 14,470 | 66.6 | 18.0 % |
| Fischer Medical Ventures Ltd | 2,355 | 96.2 | 11.4 % |
| Tarsons Products Ltd | 1,754 | 148 | 4.59 % |
| Q-Line Biotech Ltd | 1,569 | 27.8 | 22.5 % |
| Laxmi Dental Ltd | 1,058 | 30.4 | 15.0 % |
| Hemant Surgical Industries Ltd | 869 | 51.3 | 18.9 % |
| Vasa Denticity Ltd | 754 | 62.3 | 7.54 % |
| OSEL Devices Ltd | 691 | 23.6 | 24.4 % |
| Prevest Denpro Ltd | 462 | 20.5 | 24.9 % |
| Nureca Ltd | 349 | 80.4 | 3.30 % |
| Aprameya Engineering Ltd | 200 | 39.7 | 12.6 % |
| Avience Biomedicals Ltd | 198 | 22.7 | 27.0 % |
| Earkart Limited | 179 | 36.3 | 17.5 % |
| Vaidya Sane Ayurved Laboratories Ltd | 176 | 19.6 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-23 | Dividend - Re 0.50 Per Share |
| Date | Type | What it says |
|---|---|---|
| 2026-10-02 | Shareholder meeting | Voting results. |
| 2026-10-01 | Shareholder meeting | Proceedings of Annual General Meeting held on September 30, 2026 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
ESM: stage 1